Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

60 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
What is the impact of antithrombotic therapy and risk factors on the frequency of thrombovascular events in patients with metastatic breast cancer receiving epoetin beta?
Aapro M, Barnadas A, Leonard RC, Marangolo M, Untch M, Ukarma L, Burger HU, Scherhag A, Osterwalder B. Aapro M, et al. Among authors: scherhag a. Eur J Cancer. 2009 Nov;45(17):2984-91. doi: 10.1016/j.ejca.2009.06.031. Epub 2009 Jul 29. Eur J Cancer. 2009. PMID: 19646862 Clinical Trial.
Effect of once-weekly epoetin beta on survival in patients with metastatic breast cancer receiving anthracycline- and/or taxane-based chemotherapy: results of the Breast Cancer-Anemia and the Value of Erythropoietin (BRAVE) study.
Aapro M, Leonard RC, Barnadas A, Marangolo M, Untch M, Malamos N, Mayordomo J, Reichert D, Pedrini JL, Ukarma L, Scherhag A, Burger HU. Aapro M, et al. Among authors: scherhag a. J Clin Oncol. 2008 Feb 1;26(4):592-8. doi: 10.1200/JCO.2007.11.5378. J Clin Oncol. 2008. PMID: 18235117 Clinical Trial.
60 results